Athanor Capital, LP Stoke Therapeutics, Inc. Transaction History

Athanor Capital, LP

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2021 May 14, 2021	SELL	$36.08 - $69.81 $231,453 - $447,831	-6,415 Closed	0 $0
Q4 2020 Feb 16, 2021	SELL	$33.62 - $61.93 $84,554 - $155,753	-2,515 Reduced 28.16%	6,415 $397,000
Q3 2020 Nov 16, 2020	SELL	$22.23 - $37.48 $91,698 - $154,605	-4,125 Reduced 31.6%	8,930 $299,000
Q2 2020 Aug 13, 2020	BUY	$20.26 - $29.73 $264,494 - $388,125	13,055 New	13,055 $311,000
Q1 2020 May 14, 2020	SELL	$16.8 - $34.15 $162,237 - $329,786	-9,657 Closed	0 $0
Q4 2019 Feb 14, 2020	SELL	$20.01 - $30.79 $90,905 - $139,878	-4,543 Reduced 31.99%	9,657 $273,000
Q3 2019 Nov 14, 2019	BUY	$20.53 - $37.72 $291,526 - $535,624	14,200 New	14,200 $305,000

125

57.6M

9.3K

35.2K

Ticker STOK
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 39,419,300
Market Cap $367M
Description
Stoke Therapeutics, Inc., an early-stage biopharmaceutical company, develops novel antisense oligonucleotide (ASO) medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary Targeted Augmentation of Nuclear Gene Output to design ASOs to precisely upregulate protein expression. I...

Get notified when there are updates to the investment portfolio of Athanor Capital, LP, based on Form 13F filings with the SEC.

Stay updated on Athanor Capital, LP with notifications on news.